跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Vγ9Vδ2 T cell
首页
药物
Vγ9Vδ2 T cell
Vγ9Vδ2 T cell
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
IMMUNOGLOBULINS BINDING HUMAN VGAMMA9VDELTA2 T CELL RECEPTORS
EP 3129404 B1
申请人: LAVA THERAPEUTICS N V
优先权: 2014
CN
EP
US
WO
11 件公开
MATERIALS AND METHODS FOR IMPROVED EXPANSION AND USES OF IMMUNE CELLS
EP 4430198 A4
申请人: JANSSEN BIOTECH INC
优先权: 2021
EP
US
WO
3 件公开
ANTIBODIES THAT BIND GAMMA-DELTA T CELL RECEPTORS FOR THE TREATMENT OF CANCER
EP 4750809 A1
申请人: LAVA THERAPEUTICS N V
优先权: 2023
EP
US
WO
3 件公开
COMPOSITIONS COMPRISING ANTIBODIES THAT BIND GAMMA-DELTA T CELL RECEPTORS
EP 4292609 A1
申请人: LAVA THERAPEUTICS N V
优先权: 2022
EP
US
2 件公开
VARIANT ANTIBODIES THAT BIND GAMMA-DELTA T CELL RECEPTORS
EP 4292610 A1
申请人: LAVA THERAPEUTICS N V
优先权: 2022
EP
US
2 件公开
COMBINATION OF A BTN3A ACTIVATING ANTIBODY, A BCL2 INHIBITOR AND HYPOMETHYLATING AGENT FOR USE IN TREATING CANCER
US 20260256909 A1
申请人: IMCHECK THERAPEUTICS
优先权: 2022
US
WO
2 件公开
DOSES AND PHARMACEUTICAL COMPOSITIONS OF A CD33 x Vd2 BISPECIFIC ANTIBODY FOR THE TREATMENT OF CANCER
US 20260103515 A1
申请人: JANSSEN BIOTECH INC
优先权: 2024
US
WO
2 件公开
Biophosphonate compounds and gamma delta T cell-mediated therapy for treating epstein-barr virus-associated disorders
US 10532064 B2
申请人: UNIV HONG KONG
优先权: 2015
US
TREATMENT OF CANCER COMPRISING ADMINISTRATION OF VGAMMA9VDELTA2 T CELL RECEPTOR BINDING ANTIBODIES
EP 3792283 A1
申请人: LAVA THERAPEUTICS B V
优先权: 2019
EP
SELECTION OF RESPONDERS FOR ANTI-BTN3A TREATMENT
WO 2023041622 A1
申请人: IMCHECK THERAPEUTICS
优先权: 2021
WO
第 1 / 2 页
上一页
下一页
药物
反馈